You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Mallinckrodt
AstraZeneca
McKesson
Medtronic

Last Updated: April 10, 2021

DrugPatentWatch Database Preview

ZOKINVY Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Zokinvy, and when can generic versions of Zokinvy launch?

Zokinvy is a drug marketed by Eiger Biopharms and is included in one NDA.

The generic ingredient in ZOKINVY is lonafarnib. Additional details are available on the lonafarnib profile page.

Summary for ZOKINVY
US Patents:0
Applicants:1
NDAs:1
What excipients (inactive ingredients) are in ZOKINVY?ZOKINVY excipients list
DailyMed Link:ZOKINVY at DailyMed
Drug patent expirations by year for ZOKINVY
DrugPatentWatch® Estimated Generic Entry Opportunity Date for ZOKINVY
Generic Entry Date for ZOKINVY*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ZOKINVY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eiger Biopharms ZOKINVY lonafarnib CAPSULE;ORAL 213969-001 Nov 20, 2020 RX Yes No   Start Trial   Start Trial   Start Trial
Eiger Biopharms ZOKINVY lonafarnib CAPSULE;ORAL 213969-002 Nov 20, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Colorcon
Harvard Business School
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.